Last year's failure of Eli Lilly's drug semagacestat in late-stage clinical trials was the latest in a long line of setbacks for novel Alzheimer's therapies. But advances in imaging and biomarker identification are providing added impetus to ongoing drug development. Gunjan Sinha reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
De Meyer, G. et al. Arch. Neurol. 67, 949–956 (2010).
Thambisetty, M. et al. Arch. Gen. Psychiatry 67, 739–748 (2010).
Lambert, J.C. et al. Nat. Genet. 41, 1094–1099 (2009).
Harold, D. et al. Nat. Genet. 41, 1088–1093 (2009).
Bateman, R.J. et al. Ann. Neurol. 66, 48–54 (2009).
St George-Hyslop, P. et al. Nature 467, 36–37 (2010).
Mawuenyega, K.G. et al. Science 330, 1774 (2010).
Poirier, J. et al. Proc. Natl. Acad. Sci. USA 92, 12260–12264 (1995).
Furney, S.J., et al. Mol. Psych. published online, doi:10.1038/mp.2010.123 (30 November 2010).
Cruchaga, C. et al. PLoS Genet. 6, e1001101 (2010).
Hata, S. et al. Ann. Neurol. published online, doi:10.1002/ana.22343 (5 April 2011).
Clark, C. et al. J. Am. Med. Assoc. 305, 275–283 (2011).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sinha, G. Peering inside Alzheimer's brains. Nat Biotechnol 29, 384–387 (2011). https://doi.org/10.1038/nbt.1863
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1863
